Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gian Life CareBOM:542918 -0.41%59 FCF Yield % is 5.02 as of Aug. 06, 2026, which is 67% below its 10-year median of 15.01. GuruFocus rates BOM:542918 with a GF Score™ of 59/100 and a GF Value™ of ₹5.88 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Gian Life Care ranks better than 82.63% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Gian Life Care's FCF Yield % or its related term are showing as below:
BOM:542918'
s FCF Yield % Range Over the Past 10 Years
Min: 3.12 Med: 15.01 Max: 28.07
Current: 5.02
During the past 7 years, the highest FCF Yield % of Gian Life Care was 28.07%. The lowest was 3.12%. And the median was 15.01%.
BOM:542918's FCF Yield % is ranked better than 82.63% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.1
vs BOM:542918: 5.02
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Gian Life Care FCF Yield % Related Terms
Gian Life Care FCF Yield % Historical Data
* Premium members only.
The historical data trend for Gian Life Care's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542918 vs TMO, DHR, IDXX: FCF Yield % Comparison
For the Diagnostics & Research subindustry, Gian Life Care's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gian Life Care FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Gian Life Care's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Gian Life Care's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gian Life Care (BOM:542918) has a FCF Yield % of 5.02 as of Aug. 06, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Gian Life Care and its competitors. This is 67% below median its historical median of 15.01. Over the past decade, Gian Life Care's FCF Yield % has ranged from 3.12 to 28.07. According to the industry distribution chart, Gian Life Care ranks #37 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 17.4%.
Is Gian Life Care's FCF Yield % too high?
Gian Life Care's current FCF Yield % of 5.02 is 67% below median its 10-year median of 15.01. Over the past 10 years, this metric has ranged from a low of 3.12 to a high of 28.07. Based on the distribution chart, Gian Life Care ranks #37 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Gian Life Care has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gian Life Care's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Gian Life Care ranks #37 out of 213 companies for FCF Yield %. This places Gian Life Care in the top 17% of its industry — outperforming the majority of peers. Historically, Gian Life Care's own FCF Yield % has ranged from 3.12 to 28.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Gian Life Care and its competitors. Gian Life Care's current FCF Yield % is 5.02, which is 67% below median its own 10-year median of 15.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gian Life Care stock overvalued right now?
Based on GuruFocus' analysis, Gian Life Care (BOM:542918) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹5.88, compared to a current price of ₹4.91 — trading 16.5% below its estimated fair value. The current FCF Yield % is 5.02, which is 67% below median its 10-year median of 15.01. Gian Life Care's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Gian Life Care (BOM:542918), the current FCF Yield % is 5.02 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gian Life Care (BOM:542918) Overvalued in 2026?
Based on GuruFocus' analysis, Gian Life Care stock appears to be undervalued.
The current stock price of ₹4.91 is trading 16.5% below its estimated GF Value™ of ₹5.88.
GuruFocus considers Gian Life Care to be Modestly Undervalued.
Key valuation signals for BOM:542918:
FCF Yield %: 5.02 (67% below median its 10-year median of 15.01)
GF Value™: ₹5.88 vs. price of ₹4.91 (16.5% below fair value)
No single metric tells the full story. See the BOM:542918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gian Life Care Ltd is an Indian firm engaged in the business of providing diagnostic and related healthcare tests and services in Kanpur and nearby areas. The company provides a broad range of diagnostic and related healthcare tests and services such as patient diagnosis, prevention, and wellness diagnosis services to its patients and healthcare providers. Its customers include individual patients, hospitals, other healthcare providers, and corporate customers. Substantial revenue accrues from the Pathological Testing Fees. The company has only one operating segment namely, Laboratories Pathological Investigations.
59GF Score
Get the complete analysis for BOM:542918
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542918 has been successfully added to your 
